Condition
Inflammaging
Total Trials
7
Recruiting
3
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
Early P 1 (1)
Trial Status
Recruiting3
Not Yet Recruiting2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07760506Not ApplicableRecruiting
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
NCT07794956Early Phase 1Recruiting
LpD3.5 Intervention Study in Older Adults- LISA-I Trial
NCT07614542Recruiting
AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing
NCT07395921Not ApplicableNot Yet Recruiting
Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.
NCT07372417Not Yet Recruiting
Macrophage/Monocyte Driven Inflammation and Anesthetic Sensitivity in Aging
NCT04983017Not ApplicableTerminated
2021 PMT iAge® Intervention Trial by Edifice Health
NCT03308747Not ApplicableCompletedPrimary
Inflammaging and Muscle Protein Metabolism
Showing all 7 trials